Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Patients With Bulky GIST Using Sunitinib

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients more than 19 years old with pathologically proven GIST which is bulky or marginally resectable~* Patients must have at least one bidimensionally measurable disease site of 5 cm or greater not previously irradiated. Bone lesions do not qualify.~* Patients must have an ECOG performance of greater than or equal to 2, with projected survival of at least three months.~* Patients must have adequate laboratory parameters:~Hematologic: Hb \>9.0; WBC \>3200 and platelets \>100,000/mm3; Hepatic: Bilirubin \<2.0 and AST within 4 times upper limit of normal; Renal: Creatinine of less than or equal to 1.6 or eGFR greater than or equal to 50 mL/min~* Men and women who are of childbearing potential must practice strict birth control for the duration of the study.~* Women of childbearing potential must be non-lactating and non-pregnant with a negative pregnancy test within two weeks of trial registration.~* The patient, a witness, and attending physician will have signed an IRB-approved informed consent prior to Sunitinib administration.~Exclusion Criteria:~* Known brain metastases or significant pleural effusion or ascites.~* Uncontrolled hypertension, diabetes, or other medical condition.~* Major surgery within 21 days of registration.~* Patients wtih organ grafts with the exception of prior high dose chemotherapy with autologous bone marrow (or stem cell) transplantation.~* History of seizures, central nervous system disorders, dementia, or psychosis that might preclude adequate informed consent or protocol compliance.~* Prior therapy for GIST.~* A history of HIV or hepatitis virus infection.~* Any recent medical condition which, in the opinion of the investigator, makes the patient unsuitable for study participation.~* Patients with impaired kidney function.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sunitinib pill (Type: EXPERIMENTAL): Patients will receive six weeks of sunitinib and then subsequently continue for an additional 6 weeks if the evaluation at 6 weeks shows stable disease or objective response. Restaging CT scans will be performed again after 12 weeks of therapy to determine response in preparation for surgical resection anticipated to occur around week 14-16.

Based on this trial design, predict the completion outcome and termination type (if applicable).